Breaking News

AstraZeneca to Buy Respiratory Drug Company, Amirall

August 1, 2014

AZ will acquire the Catalan company, which specializes in drugs for COPD and other respiratory diseases

AstraZeneca has bought the Catalan company, Amirall's, respiratory therapies business, including rights to Eklira, a drug that is designed to treat chronic obstructive pulmonary disease (COPD) and represents 14.4% of the company's total sales. The Catalan News Agency reported this news on Wednesday, July 30, 2014.

AstraZeneca will reportedly pay $875 million initially, and up to $1.22 billion, depending on product development success, new product launches and sales.  "A significant number of employees" will reportedly be transferred to AstraZeneca, the news agency reported.   

blog comments powered by Disqus
  • Quality Risk Management

    Quality Risk Management

    Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016
    Embracing the process as a means to a strong quality culture

  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments